10672 results for 'have pump g g121'

Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does

Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu

Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest

Imagine a future where a simple blood test could detect cancer in its earliest stages, long before symptoms appear. This isn't science fiction; it's the rapidly advancing reality of liquid biopsy, a r

The Double-Edged Sword: How Neutrophil Traps Can Both Help and Hinder Cancer's Spread In the intricate battlefield of the human body, the immune system’s foot soldiers, neutrophils, have long been re

Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What

Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe

Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses

A New Era in Oncology Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the fight against cancer, offering a personalized and powerful immunotherapy that trains a patient

Quick Facts About FarletuzumabWhat is Farletuzumab?Farletuzumab is a humanized monoclonal antibody targeting folate receptor alpha (FRα), a protein overexpressed in ovarian and other epi

Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr

Cure CLCN4 2025Assay Genie was honored to attend and present at the 2025 Cure CLCN4 Scientific Conference, held on May 19–20 at Friends House in London and online. This annual event, now

Quick Facts About RituximabWhat is Rituximab?Rituximab is a monoclonal antibody targeting CD20, a protein found on the surface of B cells. It plays a crucial role in treating autoimmune

Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. By

For decades, we viewed cancer as a rogue army of cells, a biological glitch driven solely by genetic mutations and metabolic greed. We imagined tumors as isolated fortresses, growing in a vacuum of t

Imagine a future where the devastating impact of a stroke could be significantly mitigated, not just by managing symptoms, but by directly repairing the cellular machinery damaged during the event. T

Quick Info Section: Key Facts About TalquetamabWhat is Talquetamab?Talquetamab is a novel monoclonal antibody being developed for the treatment of multiple myeloma and other cancers. It

Quick Facts About VixarelimabWhat is Vixarelimab?Vixarelimab is an investigational monoclonal antibody developed to target oncostatin M receptor beta (OSMRβ), a key pathway involved in p

Cancer immunotherapy has revolutionized oncology, offering powerful new ways to treat various malignancies by harnessing the body's own immune system. Central to this success are immune checkpoint inh

What You Need to Know About CodrituzumabWhat is Codrituzumab?Codrituzumab is an investigational monoclonal antibody targeting CD47, an immune checkpoint that regulates immune responses i

For decades, the battle against cancer has focused on the cellular 'soldiers' and the genetic 'blueprints' within them. Yet, a vast, invisible world of communication exists between these cells—a secr

Why do powerful cancer immunotherapies work wonders for some patients but fail for others? The answer may lie not just in the cancer cells themselves, but in the energy levels of our own immune warrio

Imagine a world where we can fold the very fabric of life into microscopic machines, guiding the growth of a single neuron with the precision of a master architect. This isn't science fiction; it is

Dozens of cytokines converge on four kinases and seven transcription factors. That compression is the problem JAK–STAT has to solve, and it is why this map is drawn as receptor, kinase and STAT colum

What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express

The Role of CD25+FOXP3+CD45RA- Treg Cells in Cancer PrognosisIntroductionRegulatory T-cells (Treg cells) are a specialized subset of T-cells that play a pivotal role in maintaining immune homeostasis

What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-cel

As hantavirus cases continue to rise globally, the question becomes not just how to detect infections, but how to prevent them in the first place. Recent epidemiological investigations across Califor

Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leukem

Key Facts About BrentuximabWhat is Brentuximab?Brentuximab is a monoclonal antibody targeting CD30, commonly used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell

In the intricate dance between the immune system and cancer, tumors often deploy cunning strategies to evade destruction. A groundbreaking 2025 study in Nature has unveiled a startling new tactic: can

Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f

What You Need to Know About IfabotuzumabWhat is Ifabotuzumab?Ifabotuzumab is a monoclonal antibody targeting EphA3, a receptor tyrosine kinase overexpressed in certain cancers. It plays

Biologics · Bone MetabolismDenosumab: RANKL Inhibition, Clinical Applications and BiosimilarsDenosumab is a fully human monoclonal antibody against RANKL, the cytokine that drives osteoclast formation

Key Facts About EnoblituzumabWhat is Enoblituzumab?Enoblituzumab is a monoclonal antibody targeting the B7-H3 protein, which is expressed on the surface of various cancer cells, includin

Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.

Quick Facts About GirentuximabWhat is Girentuximab?Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), predominantly expressed in renal cell carcinoma (RCC) cel

Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumor

Quick Facts About BococizumabWhat is Bococizumab?Bococizumab is a monoclonal antibody that targets PCSK9, a protein involved in cholesterol regulation.How Does Bococizumab Work?It inhibi

What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis

Quick Facts About PonsegromabWhat is Ponsegromab?Ponsegromab is an investigational monoclonal antibody developed by Pfizer, primarily studied for its potential in treating heart failure

Signal 1 tells a T cell what it is looking at; signal 2 tells it whether to care. The same peptide–MHC engagement that launches a productive effector response can just as easily install an anergy pro

Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me

Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther

Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat

Imagine a mind trapped in a loop, endlessly repeating actions or thoughts, driven by an invisible force. For millions worldwide, this is the reality of Obsessive-Compulsive Disorder (OCD). While trad

Imagine a highly trained soldier, elite and effective, sent to the front lines of a relentless war. Day after day, they fight without rest, their supplies dwindle, and the enemy never stops coming. Ev

Introduction to IL-10R and Immune Suppression in CancerThe interleukin-10 receptor (IL-10R) is a key player in regulating immune responses, particularly in suppressing inflammation and ma

Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik

Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen